StockIQpro
NASDAQ:KURA

Kura Oncology, Inc.

Track all markets on TradingView
Track all markets on TradingView

Kura Oncology, Inc.'s revenue grew 25.2% in fiscal 2025 to $67.5M while operating margin fell to −449.9%. Free cash flow was −$70.7M, −104.8% of revenue, and the diluted share count rose 1.8%.Summary generated from Kura Oncology, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$67.5M
Revenue growth+25.2%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−449.9%
Net margin−412.9%
ROIC−205.5%
Return on equity−94.8%
Debt / equity0.06
Free cash flow−$70.7M
FCF margin−104.8%
Share count change+1.8%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/a05467
Operating incomen/a−140−166−193−304
Net income−130−136−153−174−279
Free cash flow−106−111−125134−71

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations